Therapy Track

The 2021 meeting will feature a dedicated Therapy track. This program has been carefully prepared to improve knowledge from patient care coordination and safety considerations, to treatment options and emerging technologies.

Saturday, January 30

10:00–11:30 am ET

The Nuts and Bolts of IV Radiopharmaceutical Therapy Administration
Sponsored by the SNMMI Therapy Center of Excellence 
Organizers: Daniel Lee, MD; Yoram Baum, MD
Moderators: Daniel Lee, MD; Tina Buehner, PhD, CNMT, FSNMMI-TS

Session Description
This is a practical session on the administration of therapeutic radiopharmaceuticals including 2 talks on techniques for intravenous administration (gravity and pump methods), a talk on acute/subacute complications of extravasations and a talk on room preparation, containing and addressing spills and contamination events, and patient education/radiation safety precautions..

Session Objectives

  1. Describe two methods of intravenous administration of radiopharmaceuticals
  2. Recognize acute/subacute complications of radiopharmaceutical extravasation
  3. Address spills and contamination events, as well as radiation safety precautions

Presentations Include:

  • Techniques of IV Therapy Administration -The Gravity Method
    Miranda Womack
  • Techniques of IV Therapy Administration – The Pump Method
    James Crowley, MHA, CNMT
  • IV Therapy Administration:  What Can Go Wrong?  Acute and Subacute Complications of Extravasations 
    Ila Sethi, MD
  • Radiation Safety Aspects in IV Therapy Administration
    Monica Johnson
  • Q&A


11:45 am–1:15 pm ET 

Prostate Cancer PSMA Therapy
Sponsored by the SNMMI Therapy Center of Excellence 
Organizers:  Ephraim E. Parent, MD, PhD; Daniel Lee, MD
Moderators: Ephraim E. Parent, MD

Session Description
Multi-disciplinary discussion regarding PSMA therapy and its role regarding other hormonal and chemotherapeutic agents.  Practical considerations regarding patient selection and administration will be discussed.

Session Objectives

  1. Describe the role of PSMA radiotherapy for prostate cancer
  2. Determine identification of ideal candidates for PSMA therapy
  3. Recognize practical considerations for PSMA radiotherapy administration

Presentations Include:

  • Medical Management of Prostate Cancer and the Role of PSMA Radiotherapy
    A. Oliver Sartor, MD
  • Patient Selection and Management of PSMA Therapy
    Phillip Kuo, MD, PhD
  • Practical Considerations of PSMA Radiotherapy Administration
    Ayse Tuba Kendi, MD
  • Q&A


2:15–3:45 pm ET

Updates on Radionuclide Therapies in Pediatrics: Current Status and Novel Applications
Sponsored by the SNMMI Therapy Center of Excellence and the SNMMI Pediatric Imaging Council
Organizers: Neeta Pandit-Taskar, MD; Victor Seghers, MD, PhD; Steve Y. Cho, MD
Moderators: Neeta Pandit-Taskar, MD; Victor Seghers, MD

Session Description
This session will provide an overview the status of MIBG therapy and explore the role of PRRT in pediatric patients. Clinical experience and trials data will be reviewed.  Novel radionuclide therapy approaches, and techniques will be discussed.

Session Objectives

  1. Examine the clinical indication, use and administration of MIBG therapy
  2. Discuss the role of PRRT in neuroblastoma
  3. Recognize novel targeting agents for treatment of pediatric tumors

Presentations Include:

  • The Role of PRRT in NB
    Jennifer E. Gaines, MD
  • Thyroid Cancer – ATA Guidelines and Case Discussion
    Adina L. Alazraki, MD
  • Novel Agents and Approaches for Treating Pediatric Tumors
    Neeta Pandit-Taskar, MD
  • MIBG Therapies in NB
    Susan E. Sharp, MD
  • Q&A


4:15–5:45 pm ET

Updates and Clinical Applications of PRRT for NET
Sponsored by the SNMMI Therapy Center of Excellence 
Organizers: Neeta Pandit-Taskar, MD; Steve Y. Cho, MD
Moderators: Steve Y. Cho, MD; Neeta Pandit-Taskar, MD

Session Description
This session will overview specific topic discussions in molecular imaging and peptide receptor radioligand therapy (PRRT) for neuroendocrine tumors (NET), including gastroenteropancreatic (GEP), pheochromocytomas and paragangliomas.  We will review current practice, case discussions and novel emerging approaches.

Session Objectives

  1.  List the basic principles of PRRT and its oncologic applications in NET
  2.  Define the current indications, contraindications, and response assessments for PRRT in GEP
  3.  Examine emerging PRRT applications in pheochromocytoma and paraganglioma

Presentations Include:

  •  Clinical Oncology Diagnosis and Treatments for NET
    Jennifer R. Eads, MD
  •  Current and Emerging Molecular Imaging and PRRT for NET
    Grace Kong, MD
  •  Current and Emerging Molecular Imaging for PRRT for Pheochromocytoma and Paraganglioma
    Frank Lin, MD
  •  Case Series on PRRT in NET (Interactive SAM Session)
    Steve Y. Cho, MD
  •  Q&A


6:00–7:30 pm ET


Radioiodine Therapy for Differentiated Thyroid Cancer
Sponsored by the SNMMI Therapy Center of Excellence 
Organizer/Moderator: Frederick D. Grant, MD

Session Description
Although radioiodine (I-131) therapy for thyroid cancer has been one of the mainstays of nuclear medicine practice for decades, the indications and perceived utility of this therapy continue to evolve. Speakers in this session will review the current use of radioiodine therapy from the perspective of a clinical endocrinologist, present an approach to radioiodine therapy from the perspective of a nuclear medicine physician, and discuss current thinking regarding the potential risks and late effects of radioiodine therapy.

Session Objectives

  1.  Discuss the evolving endocrinology perspective on the use of radioiodine therapy for differentiated thyroid cancer.
  2.  Describe the use of radioiodine (I-131) for the treatment of differentiated thyroid cancer
  3.  Summarize potential risks and late effects of radioiodine (I-131) therapy.

Presentations Include:

  •  The Clinical Endocrinologist's Evolving Perspective on the Use of Radioactive Iodine for Differentiated Thyroid Carcinoma
    Erik K. Alexander, MD
  •  Radioiodine (I-131) Treatment of Differentiated Thyroid Cancer: The Nuclear Medicine Perspective
    Robert Flavell, MD, PhD
  •  Potential Risks and Late Effects of Radioiodine (I-131) Therapy
    Bennett S. Greenspan, MD, FACNM, FACR, FSNMMI
  •  Q&A